Skip to main content

Advertisement

SpringerLink
Log in

Pathological and prognostic significance of matrix metalloproteinase-2 expression in ovarian cancer: a meta-analysis

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Matrix metalloproteinase-2 (MMP-2) has been linked with tumor invasion and metastasis. However, the role of MMP-2 expression in ovarian cancer remains controversial. By searching the PubMed, Embase, Wanfang, and China National Knowledge Infrastructure databases, we conducted a meta-analysis to evaluate the pathological and prognostic significance of MMP-2 in ovarian cancer. Studies were pooled, and the odds ratio (OR) and its corresponding 95 % confidence interval (CI) were calculated. Version 11.0 STATA software was used for statistical analysis. Twenty-seven relevant articles were included for this meta-analysis study. The expression of MMP-2 in cancer tissue was significantly higher than that in benign or normal ovarian tissue [cancer vs. benign, OR 10.09 (95 % CI 6.95–14.64); P < 0.001; cancer vs. normal, OR 30.48 (95 % CI 17.19–54.05); P < 0.001; benign vs. normal, OR 1.88 (95 % CI 1.08–3.29); P = 0.025]. The expression of MMP-2 in stage III–IV or lymph node metastasis was significantly higher than that in stage I–II or that without metastasis, respectively [OR 5.83 (95 % CI 4.32–7.85); P < 0.001; OR 7.20 (95 % CI 4.75–10.91); P < 0.001]. MMP-2 was associated with histological types and grade of ovarian cancer [serous vs. mucinous, OR 1.67 (95 % CI 1.17–2.39); P = 0.004; grade 3 vs. 1, 2, OR 3.23 (95 % CI 2.29–4.55); P < 0.001]. However, the age of patients was not associated with MMP-2 expression [OR 1.25 (95 % CI 0.61–2.58); P = 0.546]. In conclusion, MMP-2 is related to the malignant degree, FIGO stage, histological types and grade, and lymph node metastasis of ovarian cancer. It may play a significant role in clinical guidelines for the treatment and prognostic evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin. 2012;62:10–29.

    Article  PubMed  Google Scholar 

  2. Chiang YC, Chen CA, Chiang CJ, et al. Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. J Gynecol Oncol. 2013;24:342–51.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Vincenti MP, White LA, Schroen DJ, Benbow U, Brinckerhoff CE. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryo Gene Expr. 1996;6:391–411.

    Article  CAS  Google Scholar 

  4. Galateau-Salle FB, Luna RE, Horiba K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. Hum Pathol. 2000;31:296–305.

    Article  CAS  PubMed  Google Scholar 

  5. Collier IE, Wilhelm SM, Eisen AZ, et al. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem. 1988;263:6579–87.

    CAS  PubMed  Google Scholar 

  6. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274:21491–4.

    Article  CAS  PubMed  Google Scholar 

  7. Kolkenbrock H, Hecker-Kia A, Orgel D, Ulbrich N, Will H. Activation of progelatinase A and progelatinase A/TIMP-2 complex by membrane type 2-matrix metalloproteinase. Biol Chem. 1997;378:71–6.

    Article  CAS  PubMed  Google Scholar 

  8. O-Charoenrat P, Khantapura P. The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol. 2006;42:257–67.

    Article  CAS  PubMed  Google Scholar 

  9. Wu X, Li H, Kang L, Li L, Wang W, Shan B. Activated matrix metalloproteinase-2-a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol. 2002;84:126–34.

    Article  CAS  PubMed  Google Scholar 

  10. Kamel H, Abdelazim I, Habib SM, El Shourbagy MA, Ahmed NS. Immunoexpression of matrix metalloproteinase-2 (MMP-2) in malignant ovarian epithelial tumours. J Obstet Gynaecol Can. 2010;32:580–6.

    Article  PubMed  Google Scholar 

  11. Abdelazim IA, Al-Kadi M. Immunoexpression of matrix metalloproteinase-2 (MMP-2) in epithelial ovarian cancers (EOCs). Asian Pac J Reprod. 2013;2:136–41.

    Article  Google Scholar 

  12. Lin CK, Chao TK, Yu CP, Yu MH, Jin JS. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. APMIS. 2009;117:162–75.

    Article  CAS  PubMed  Google Scholar 

  13. Manenti L, Paganoni P, Floriani I, et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer. 2003;39:1948–56.

    Article  CAS  PubMed  Google Scholar 

  14. Cai KQ, Yang WL, Capo-Chichi CD, et al. Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis. Mol Carcinog. 2007;46:130–43.

    Article  CAS  PubMed  Google Scholar 

  15. Torng PL, Mao TL, Chan WY, Huang SC, Lin CT. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecol Oncol. 2004;92:559–67.

    Article  CAS  PubMed  Google Scholar 

  16. Zhang H. Expression and clinical significance of GLUT-1 and MMP-2 in the tissue of human malignant ovarian tumor. Wanfang Master Thesis Database. 2005.

  17. Wu JX, Zhao Y, Jia SJ, Li YY. Expressions of MMP-2, MMP-3, MMP-9 and CD147 in human ovarian cancer and their clinicopathological significance. J Chongqing Med Univ. 2007;32:1165–8.

    Google Scholar 

  18. Wang J. Expression and significance of osteopontin, MMp-2 in epithelial ovarian tumor. Wanfang Master Thesis Database. 2007.

  19. Luo YH, He AB, Zhang YQ. The unbalanced expression of MMP-2 and TIMP-2 and its correlations with angiogenesis in epithelial ovarian neoplasm. An Hui Yi Xue. 2007;28:88–90.

    Google Scholar 

  20. Zhang Y, Chen Y, Wei L. Expressions of VEGF165 and MMP2 in epithelial ovarian cancer. J Clin Res. 2008;25:1968–70.

    CAS  Google Scholar 

  21. Pan Y, Zhu D, Si N, Zhang W. Expressions of RhoC and MMP-2 proteins in epithelial ovarian cancer tissues and their clinical significances. J Jilin Univ. 2008;34:1042–5.

    CAS  Google Scholar 

  22. Liu Y, Zhang Y, Kuang H, Kong C. Expression of MMP2 protein in epithelial ovarian cancer tissue. China Trop Med. 2008;8:1694–5.

    CAS  Google Scholar 

  23. Zhu G. Expression and significance of OPN, CD44v6, MMp-2 in epithelial ovarian tumor. Wanfang Master Thesis Database. 2008.

  24. Li H, Su Y, Wu J, Zhang J, Dou Z, Li Y. Expression and clinical significance of MMP-2 and VEGF in ovarian carcinoma. Chin J Lab Diagn. 2009;13:726–9.

    Google Scholar 

  25. Sun H, Yan X, Li R, Wang X, Zhang Y. Expression and significance of CXCR4 and MMP-2 in human ovarian epithelial tumors. Zhong Liu Fang Zhi Yan Jiu. 2009;36:747–9.

    Google Scholar 

  26. Wang T. Explore the relationship between VEGF and MMP-2 and ovarian cancer ascites and abdominal metastases. Pract Prev Med. 2009;16:1531–2.

    CAS  Google Scholar 

  27. Liu Y, Lv J, Chen Y, Lin M. Expressions of claudin-4 and MMP-2 in epithelial ovarian tumor. Oncol Progr. 2009;7:563–9.

    Google Scholar 

  28. Zeng X, Peng Y. Expression and clinical significance of VEGF, MMP-2 and MMP-9 in ovarian carcinoma. Prog Mod Biomed. 2010;10:2322–4.

    CAS  Google Scholar 

  29. Guo J. The expression of HGF, IGF-I and MMP-2 in epithelial ovarian cancer. Wanfang Master Thesis Database. 2010.

  30. Yu L, Wang W, Gan H, Wu S, Song W, Guo B. Expression and clinical significance of MMP-2 and MMP-7 in ovarian carcinoma. Chin J Histochem Cytochem. 2011;20:325–30.

    CAS  Google Scholar 

  31. Hu J. Expression of MMP2 and MMP9 in tissue of epithelial tumor of ovary and its clinical significance. Chin Med Mod Distance Educ China. 2011;9:208–10.

    Google Scholar 

  32. Su M, Zhang Y, Huang H, Shi G, Sun F, Qiu Y. Expression of HIF-1A and MMP-2 in vasculogenic mimicry of ovarian cancer. Prog Obstet Gynecol. 2011;2:83–7.

    Google Scholar 

  33. Shen L, Tang L, Zhang J, Zhou S. Expression and significance of WAVE1, MMP-2 and MMP-9 in ovarian cancer. J Third Mil Med Univ. 2013;35:1406–9.

    CAS  Google Scholar 

  34. Wang L, Jin X, Lin D, et al. Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases -2 expression in ovarian carcinoma. Diagn Pathol. 2013;8:190.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Grelewski PG, Bar JK. The role of p53 protein and MMP-2 tumor/stromal cells expression on progressive growth of ovarian neoplasms. Cancer Invest. 2013;31:472–9.

    Article  CAS  PubMed  Google Scholar 

  36. Li S, Mei J. Clinical significance of MMP-2 and COX-2 expression in epithelial ovarian cancers. J Wannan Med Coll. 2013;32:283–6.

    Google Scholar 

  37. Wu D, Yang J, Yao Y, Zhou Q. Expression and significance of MMP- 2 and its inhibitors in epithelial ovarian carcinoma. Proc Clin Med. 2013;22:650–2.

    Google Scholar 

  38. Brown MR, Blanchette JO, Kohn EC. Angiogenesis in ovarian cancer. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;14:901–18.

    Article  CAS  PubMed  Google Scholar 

  39. Arnold JM, Cummings M, Purdie D, Chenevix-Trench G. Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas. Br J Cancer. 2001;85:1351–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Beijing Friendship Hospital, Capital Medical University, 95 Yong-An Road, Beijing, 100050, China

    Chao Liu

Authors
  1. Chao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chao Liu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, C. Pathological and prognostic significance of matrix metalloproteinase-2 expression in ovarian cancer: a meta-analysis. Clin Exp Med 16, 375–382 (2016). https://doi.org/10.1007/s10238-015-0369-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-015-0369-y

Keywords

Search

Navigation